Pathway analysis of the differentially expressed genes between wild-type and mutant ARF cell lines demonstrated that Wnt pathway components may act downstream of ARF signaling, contributing to tumor development when ARF activity is compromised [89]. The gene discussed is CDKN2A; the disease is neoplasm.